Vascular contribution to dementia in Parkinson's disease

Neurodegenerative Diseases

Volumn 7, Issue 1-3, 2010, Pages 127-130

  Korczyn, Amos D ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Dementia; Parkinson's disease; Vascular lesions

Indexed keywords

CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO;

BRAIN CORTEX; CLINICAL FEATURE; COGNITIVE DEFECT; CONFERENCE PAPER; DEMENTIA; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; COGNITION DISORDERS; DEMENTIA; HUMANS; PARKINSON DISEASE;

EID: 76749155735     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000285522     Document Type: Conference Paper

References (31)

1. Klein C: Implications of genetics on the diagnosis and care of patients with Parkinson disease. Arch Neurol 2006; 63: 328-334.
2. Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H: Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002; 61: 413-426.
3. Korczyn AD, Gurevich T: Parkinson's disease: before the motor symptoms and beyond. J Neurol Sci, accepted.
4. Butler TC, van den Hout A, Matthews FE, et al: Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008; 70: 1017-1022.
5. Korczyn AD: Dementia in Parkinson's disease. J Neurol 2001; 248(suppl 3):1-4.
6. Bower JH, Dickson DW, Taylor L, Maraganore DM, Rocca WA: Clinical correlates of the pathology underlying parkinsonism: a population perspective. Mov Disord 2002; 17: 910-916.
7. Weiner MF, Risser RC, Cullum CM, et al: Alzheimer's disease and its Lewy body variant: a clinical analysis of postmortem verified cases. Am J Psychiatry 1996; 153: 1269-1273.
8. Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD: Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand 2003; 108: 368-373. (Pubitemid 37357643)
9. Emre M, Aarsland D, Albanese A, et al: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518.
10. Whitehouse PJ, Hedreen JC, White CI, Price DI: Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 1983; 13: 243-248.
11. Korczyn AD: Mixed dementia - the most common cause of dementia. Ann NY Acad Sci 2002; 977: 129-134.
12. Schneider JA, Troncoso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova O, O'Brien RJJ: Effect of infarcts on dementia in the Baltimore longitudinal Study of aging. Ann Neurol 2008; 64: 168-176.
13. Papapetropoulos S, Argyriou AA, Ellul J: Clinical characteristics of late-onset Parkinson disease. Arch Neurol 2003; 60: 1815-1816.
14. Balash Y, Korczyn AD: Vascular parkinsonism; in Koller WC, Melamed E (eds): Handbook of Clinical Neurology. Parkinson's Disease and Related Disorders. Part 2. Amsterdam, Elsevier, 2007, pp 417-425.
15. Ben-Shlomo Y, Whitehead AS, Smith GD: Parkinson's, Alzheimer's, and motor neurone disease. BMJ 1996; 312: 724.
16. Schneider JA, Arvanitakis Z, Bang W, Bennett DA: Mixed brain pathologies account for most dementia cases in communitydwelling older persons. Neurology 2007; 69: 2197-2204.
17. Beyer MK, Larsen JP, Aarsland D: Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology 2007; 69: 747-754.
18. Thompson PD, Marsden CD: Gait disorder of subcortical arteriosclerotic encephalopathy: Binswanger's disease. Mov Disord 1987; 2: 1-8.
19. Hughes AJ, Daniel SE, Lees AJ: Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57: 1497-1499.
20. Snowdon DA, Greiner LH, Mortimer JA, et al: Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277: 813-817.
21. Groswasser IR, Bornstein NM, Korczyn AD: Parkinsonism in patients with lacunar infarcts of the basal ganglia. Eur Neurol 1995; 35: 46-49.
22. Tolosa ES, Santamaria J: Parkinsonism and basal ganglia infarcts. Neurology 1984; 34: 1516.
23. Annanmaki T, Pessala-Driver A, Hokkanen L, Murros K: Uric acid associates with cognition in Parkinson's disease. Parkinsonism Relat Disord 2008; 14: 576-578.
24. Sachdev P, Parslow R, Salonikas C, et al: Homocysteine and the brain in midadult life: evidence for an increased risk of leukoaraiosis in men. Arch Neurol 2004; 61: 1369-1376.
25. Korczyn AD: Catechol-O-methyl transferase inhibitors in the treatment of Parkinson's disease; in Galvez-Jimenez N (ed): Scientific Basis for the Treatment of Parkinson's Disease. London, Taylor and Francis, 2005, pp 145-150.
26. O'Suilleabhain PE, Sung V, Hernandez SV, Lacritz L, et al: Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004; 61: 865-868.
27. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz- Arrastia R: Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003; 60: 59-64.
28. Barone P, Burn DJ, van Laar T, Hsu C, Poewe W, Lane RM: Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Mov Disord 2008; 23: 1532-1540.
29. Slawek J, Wieczorek D, Derejko M, Dubaniewicz M, Brockuis B, Sitek E, Wilczewska L, Roszman A, Lass P: The influence of vascular risk factors and white matter hyperintensities on the degree of cognitive impairment in Parkinson's disease. Neurol Neurochir Pol 2008; 42: 505-512.
30. Haugarvoll K, Aarsland D, Wentzel-Larsen T, Larsen JP: The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's Disease. Acta Neurol Scand 2005; 112: 386-1339
31. Rektor I, Goldemund D, Sheardova K, Rektorova I, Michalkova Z, Dufek M: Vascular pathology in patients with idiopathic Parkinson's Disease. Parkinsonism Relat Disord 2009; 15: 24-29.